-
Product Insights
NewUnited Kingdom (UK) Protection Insurance – Whole of Life Assurance
United Kingdom (UK) Protection Insurance Market Report Overview The number of contracts in the UK’s individual protection market declined in 2022. The total number of contracts issued was 2.2 million. Premiums rose 0.1%, mainly led by an increase in income protection and critical illness. However, inflation and the cost-of-living crisis have caused financial constraints for many consumers, making it difficult for them to afford insurance. The United Kingdom (UK) protection insurance report analyses the market drivers, competitive landscapes, and key...
-
Product Insights
New![]()
Net Present Value Model: Atai Life Sciences NV’s Noribogaine
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Kezar Life Sciences Inc’s Zetomipzomib
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Atai Life Sciences NV’s Dimethyltryptamine
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Atai Life Sciences NV’s Ibogaine
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Atai Life Sciences NV's Ibogaine Drug Details: Ibogaine is under development for the treatment of opioid use disorder. Ibogaine is a natural indole...
-
Product Insights
New![]()
Net Present Value Model: Atai Life Sciences NV’s PCN-101
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
